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syndrome
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Lifestyle‑induced weight loss is regarded as an efficient therapy to reverse metabolic syndrome (MetS) 
and to prevent disease progression. The objective of this study was to investigate whether lifestyle‑
induced weight loss modulates gene expression in circulating monocytes. We analyzed and compared 
gene expression in monocytes  (CD14+ cells) and subcutaneous adipose tissue biopsies by unbiased 
mRNA profiling. Samples were obtained before and after diet‑induced weight loss in well‑defined 
male individuals in a prospective controlled clinical trial (ICTRP Trial Number: U1111‑1158‑3672). The 
BMI declined significantly (− 12.6%) in the treatment arm (N = 39) during the 6‑month weight loss 
intervention. This was associated with a significant reduction in hsCRP (− 45.84%) and circulating 
 CD14+ cells (− 21.0%). Four genes were differentially expressed (DEG’s) in  CD14+ cells following weight 
loss (ZRANB1, RNF25, RB1CC1 and KMT2C). Comparative analyses of paired  CD14+ monocytes and 
subcutaneous adipose tissue samples before and after weight loss did not identify common genes 
differentially regulated in both sample types. Lifestyle‑induced weight loss is associated with specific 
changes in gene expression in circulating  CD14+ monocytes, which may affect ubiquitination, histone 
methylation and autophagy.
Metabolic syndrome (MetS) represents a cluster of risk factors for cardiovascular disease (CVD) and type 2 
diabetes mellitus. Experimental and observational evidence suggests that obesity-associated inflammation plays 
a central role in metabolic dysfunction and disease progression. Adipose tissue is primarily composed of adipo-
cytes and immune cells such as macrophages. It has been increasingly recognized as a major source of circulating 
proinflammatory cytokines, which are typically observed in obesity-associated metabolic  dysfunction1. Follow-
ing prolonged caloric overload and adipocyte hypertrophy, IL-6 and other proinflammatory molecules such 
as MCP-1 (monocyte chemoattractant protein-1) are secreted by adipocytes  themselves2. Obesity-associated 
adipose tissue inflammation promotes the accumulation of adipose tissue macrophages (ATMs), which may be 
derived either from peripheral blood monocytes or from local macrophage  proliferation3. ATMs interacting with 
hypertrophic adipocytes promote insulin resistance and inflammation of adipose tissue. ATM frequency and 
proinflammatory gene expression in adipose tissue are positively associated with adipocyte size and negatively 
associated with weight loss in  obesity4,5.
A possible source of proinflammatory ATMs is peripheral circulating monocytes. Monocyte frequency is 
elevated in overweight and obese individuals compared with lean  individuals6. Moreover, elevated monocyte 
frequency is associated with an increased risk for cardiovascular  disease7. Experimental models imply that 
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obesity-associated metabolic stress promotes the “priming of circulating monocytes” i.e., hypersensitization of 
blood monocytes to chemokines, resulting in increased recruitment of monocyte-derived macrophages into 
the sites of  inflammation8,9. Thus, obesity-associated changes in peripheral blood monocytes may promote the 
progression of adipose tissue inflammation and aggravate obesity-associated metabolic dysfunction.
Lifestyle-induced weight loss significantly improves metabolic and cardiovascular outcomes in patients with 
 MetS10. This suggests that not only the frequency but also the gene expression profile of peripheral blood mono-
cytes may change upon weight loss. Our study addresses the question of whether lifestyle-induced weight loss 
modulates the gene expression of peripheral circulating blood monocytes in individuals with MetS who are 
at high risk for type 2 diabetes mellitus and CVD. We analyzed and compared the gene expression profiles of 
paired  CD14+ monocyte samples and corresponding adipose tissue samples before and after lifestyle-induced 
weight loss in well-defined individuals with MetS in a prospective controlled clinical trial (ICTRP Trial Number: 
U1111-1158-3672).
Results
Clinical and laboratory measurements. Before and after the 6-month period, clinical parameters and 
body composition were determined in participants of both arms. The analyzed study population did not differ in 
the distribution of age, sex or parameters of MetS at baseline (Table 1, Supplementary Table S3).
Participants in the treatment arm reduced their individual BMI by 12.6%. Other significantly changed param-
eters included decreased serum levels of triglycerides (− 30.5%), LDL cholesterol (− 11.9%), HOMA-IR (− 48.7%), 
leptin (− 62.6%), IL-6 (− 4.7%) and hsCRP (− 45.4%).
Following the 6-month observational period, participants of the control arm significantly increased BMI 
(1.8%) and total body fat mass (5.2%). No other significant changes were observed.
In both arms, no progression to overt type 2 diabetes was observed during the 6-month period. In general, 
the changes in these clinical and laboratory measurements are comparable with those obtained in the whole 
cohort that initially completed the  study11.
CD14+ cells. Although lifestyle-induced weight loss had no effect on total leukocyte levels, the frequency of 
 CD14+ cells was significantly decreased (− 21.0%). The purity of  CD14+ cells, as quantified by FACS, was between 
99.0 and 99.4% (Table 2), indicating that the obtained results are not confounded by  CD14− blood cells. 
To assess the relationship between  CD14+ cell frequencies and clinical or laboratory parameters character-
istic of MetS, we determined bivariate correlations (Supplementary Table S1). The relative changes in  CD14+ 
cell frequencies were positively correlated with BMI (r = 0.37; p < 0.009), leptin (r = 0.43; p < 0.002) and hsCRP 
(r = 0.35; p < 0.016) (Fig. 1, Supplementary Fig. S1).
Gene expression analysis. To identify differentially expressed genes in  CD14+ cells following lifestyle-
induced weight loss, gene expression was analyzed by microarray analysis. Raw data were normalized to com-
pensate for systematic variation (Supplementary Fig. S2). After normalization, we calculated a median coeffi-
cient of variation (CV) of 4.08% across all cells in the experiment (78 samples × 53,617 cells). All samples were 
included for differential gene expression analysis.
PCA was used to visualize the variance of the gene expression data in the weight loss group. The first principal 
component (PC1) on the x-axis accounts for most of the variation in the dataset. The second principal component 
(PC2), located on the y-axis, captures the second largest percentage of variance. Surprisingly, the PCA analysis did 
not clearly separate the two observational time points (treatment arm before and after the 6-month intervention 
period), indicating that gene expression in  CD14+ cells remained largely unaffected despite weight loss (Fig. 2).
Differential gene expression was separately analyzed in paired  CD14+ samples from the treatment and the 
control arm. The false discovery rate was controlled by correction for multiple testing using the Benjamini–Hoch-
berg method. We identified four protein coding genes in paired  CD14+ samples of the treatment arm that were 
differentially expressed after the 6-month intervention period (Table 3) namely, ZRANB1 (zinc finger RANBP2-
type containing 1; adj. p = 0.006, log fold change = − 0.307), RNF25 (ring finger protein 25; adj. p = 0.049, log fold 
change = 0.24), RB1CC1 (adj. p = 0.049, log fold change = − 0.16) and KMT2C (Lysine Methyltransferase 2C; adj. 
p = 0.049, log fold change =  − 0.20).
Comparative analyses of gene expression of paired  CD14+ monocyte samples and corresponding subcutane-
ous adipose tissue samples (N = 36) did not identify common genes differentially regulated in both sample types 
(Fig. 3, Table 3). Hence, the altered gene expression observed for the four genes was specific for  CD14+ cells.
Subgroup analysis in individuals with a large change in hsCRP. As the reduced frequency of 
peripheral  CD14+ cells was positively correlated with hsCRP, we speculated this may reflect an improvement 
in obesity-associated low-grade inflammation upon weight loss. Thus the altered gene expression may be more 
pronounced in individuals with a significant reduction in hsCRP. To this end, we performed a subgroup analysis, 
including only individuals from the treatment arm, in which the elevated hsCRP levels declined by at least 50% 
(N = 16, hsCRP subgroup, Fig. 4). Clinical and laboratory parameters of the hsCRP subgroup are shown in Sup-
plementary Table S2. Weight loss and clinical parameters were comparable between the hsCRP subgroup and 
the entire treatment arm except for inflammatory markers hsCPR and IL-6, which were more strongly reduced 
in the hsCRP subgroup (see Table 1, Supplementary Table S2).
However, PCA analysis did not show clear separation when comparing gene expression before and after 
weight loss in the hsCRP subgroup (Supplementary Fig. S3). Furthermore, we did not observe significant gene 
expression alterations following correction for multiple testing.
3
Vol.:(0123456789)
Scientific Reports |        (2020) 10:17855  | https://doi.org/10.1038/s41598-020-74973-2
www.nature.com/scientificreports/
Table 1.  Clinical parameters of individuals with MetS before and after the 6-month treatment period. Data 
are presented as the median (interquartile range, IQR). BMI Body Mass Index, HDL high-density lipoprotein 
cholesterol, LDL low-density lipoprotein cholesterol, HOMA-IR homeostasis model of assessment index, IL-6 
interleukin-6, hsCRP high sensitive C-reactive protein, WBC white blood cell count. The Wilcoxon Signed-
Rank test was used to analyze differences in paired samples of the treatment arm (N = 39) and the control arm 
(N = 12), *p < 0.05, **p < 0.01, ***p < 0.001. No differences were found between both arms with regard to age 
and BMI before weight loss (Mann–Whitney U test).
Treatment arm Control arm





Median 33.6 28.8*** 33.4 34.14***
IQR (31.2–35.6) (26.5–31.6) (32.4–35.4) (33.1–35.5)
Body weight (kg)
Median 108 93.5*** 103 104*
IQR (99.0–117) (84.5–106) (96.8–109) (98.7–110)
Triglycerides (mmol/l)
Median 1.90 1.26*** 2.02 2.26*
IQR (1.39–2.85) (0.95–1.8) (1.57–3.19) (1.87–3.61)
Total cholesterol (mmol/l)
Median 6.08 5.20** 5.94 6.05
IQR (4.85–6.69) (4.33–6.25) (5.17–7.13) (4.78–7.08)
HDL-cholesterol (mmol/l)
Median 1.21 1.45*** 1.28 1.29
IQR (1.05–1.41) (1.22–1.61) (1.10–1.63) (1.05–1.59)
LDL-cholesterol (mmol/l)
Median 3.50 3.18* 3.57 3.40
IQR (2.71–4.35) (2.40–4.01) (2.76–4.81) (2.52–4.14)
Free fatty acids (mmol/l)
Median 0.55 0.50 0.63 0.53
IQR (0.42–0.71) (0.35–0.59) (0.51–0.90) (0.41–0.80)
HOMA-IR
Median 3.13 1.29*** 2.10 2.11*
IQR (1.89–5.00) (0.91–2.40) (1.55–3.10) (1.71–3.45)
Total fat mass (kg)
Median 31.9 23.8*** 26.1 28.9*
IQR (25.9–36.7) (20.5–29.3) (23.9–35.4) (23.8–36.3)
Leptin (ng/ml)
Median 12.5 5.57*** 10.1 12.8***
IQR (8.06–17.2) (2.82–8.75) (7.55–19.9) (7.85–18.4)
IL-6 (pg/ml)
Median 2.70 2.20* 1.85 2.05
IQR (1.90–4.00) (1.90–2.80) (1.50–2.57) (1.50–4.00)
hsCRP (mg/l)
Median 3.40 1.10*** 3.70 2.20
IQR (1.30–6.60) (0.60–3.60) (1.25–5.87) (1.27–4.82)
WBC (Gpt/l)
Median 6.25 6.20 6.70 6.95
IQR (5.30–7.70) (4.70–7.30) (5.97–7.65) (6.13–7.77)
CD14+ cell frequencies (107/20 ml)
Median 1.10 0.80* 1.29 1.10
IQR (0.80–1.40) (0.50–1.40) (0.98–1.70) (1.00–1.37)
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Discussion
Recent studies suggest that obesity-associated inflammatory mediators drive functional adaptations of circulat-
ing peripheral blood monocytes towards a proinflammatory  phenotype12–14. According to the expert panel of 
the AHA/ACC/TOS, lifestyle-induced weight loss reduces the risk of developing type 2 diabetes mellitus and 
 CVD10. Hence, we hypothesized that lifestyle-induced weight loss may modulate gene expression in peripheral 
blood monocytes and that genes regulated in monocytes upon weight loss could serve as potential biomarkers 
or even therapeutic targets. This hypothesis was tested using an unbiased approach in a well-characterized and 
well-matched cohort.
Following lifestyle-induced weight loss we identified four differentially expressed genes in  CD14+ monocytes 
(ZRANB1, RNF25, RB1CC1 and KMT2C). The downregulated gene ZRANB1, which is also known as Trabid 
(TRAF-binding protein domain), encodes the K29- and K33-specific deubiquitinase  ZRANB115. ZRANB1 has 
been shown to regulate the Wnt signaling  pathway16 and to play a role in the regulation of cell morphology 
and cytoskeletal  organization17. Moreover ZRANB1 deficiency in macrophages and dendritic cells impairs the 
induction of IL-12 and IL-23 by the regulation of histone modifications at the IL-12 promoter, indicating a role 
of ZRANB1 in mediating inflammatory  responses18 and macrophage  activation19.
The upregulated RNF25 encodes a ubiquitin E3 ligase that has been identified as an interacting protein 
with the transactivation domain of the p65 subunit of NF-κB20. Hence RNF25 may promote NF-κB-induced 
Table 2.  Quality control of  CD14+ samples and total RNA obtained. The RNA integrity number (RIN) gives 
the quality of the extracted RNA. Data are presented as the median (interquartile range, IQR).
Treatment arm Control arm
Before 6 month Before 6 month
CD14+, CD3– FACS (%)
Median 99.2 99.0 99.4 99.3
IQR (98.6–99.5) (98.6–99.4) (99.2–98.7) (98.4–99.4)
RNA QC (RIN)
Median 9.70 9.90 9.40 9.75
IQR (9.60–9.80) (9.60–10.0) (9.20–9.70) (9.50–9.87)
Figure 1.  Relationship between changes in  CD14+ cell frequencies and clinical or laboratory parameters. 
Spearman correlation (2-tailed) was used to analyze the correlation between relative changes in  CD14+ cell 
frequencies and BMI (a), leptin (b) or hsCRP (c) in participants of both arms. Data are shown as individual data 
points. The regression line is given as the mean ± 95% confidence interval.
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inflammation. Moreover, its RING finger motif has been shown to bind to ubiquitin-conjugating enzymes and 
to promote E2-dependent  ubiquitination21.
The upregulated gene RB1CC1 encodes the RB1-inducible coiled-coil protein 1, which is known to promote 
autophagosome formation through direct interaction with  Atg16L122.
In addition, we observed a downregulation of KMT2C, which encodes the histone methyltransferase Lysine 
N-methyltransferase 2C that regulates gene transcription by mediating mono- and tri-methylation of histone 
H3 at lysine  423.
Taken together identified genes regulate ubiquitination, autophagy and histone methylation in  CD14+ mono-
cytes. Our results indicate that ubiquitination and autophagosome formation might be increased following 
lifestyle-induced weight loss. Autophagy is a cellular degradation pathway which maintains cellular homeostasis 
through degradation and recycling of cellular proteins in response to environmental conditions. It has been 
shown that insulin inhibits the activation of autophagy by mTOR (mechanistic target of rapamycin)24. Hence, 
we hypothesize that weight loss associated insulin reduction may cause observed induction of autophagy and 
ubiquitination in  CD14+ monocytes. The net-effect on monocyte function induced by the altered expression 
of these four genes, which regulate fundamental pathways related to ubiquitination, histone methylation and 
autophagy, needs to be analyzed in detail in future studies.
Serum levels of adipose tissue-related proinflammatory cytokines correlate strongly with CRP, which is pre-
dominantly produced in hepatocytes but also by local macrophages, endothelial cells or adipocytes upon IL-6 
 stimulation25. CRP has been recognized as a relevant prognostic risk factor for cardiovascular disease, especially 
in association with abdominal  obesity26. In the present study, plasma levels of IL-6 and CRP were increased before 
the intervention, reflecting obesity-associated chronic low-grade inflammation at baseline, and significantly 
declined following lifestyle-induced weight loss. The reduction in inflammatory markers is in line with other 
studies that investigated the effect of weight loss by lifestyle changes or by surgical interventions. Overall, weight 
loss has been associated with a linear decline in CRP  levels27. Accordingly, we observed a strong correlation 
between changes in hsCRP levels and BMI during the 6-month intervention.
Together with elevated proinflammatory mediators, increased levels of monocyte frequencies have been 
reported in overweight and obese compared with lean  individuals6. An increased frequency of monocytes has 
been proposed to aggravate obesity-associated low-grade  inflammation28. In our study, we observed a decline 
in peripheral  CD14+ cell frequencies following lifestyle-induced weight loss. Participants of the treatment arm 
were instructed to increase physical activity, to reduce calorie intake and to perform a low-carbohydrate diet 
with preference for low-GI carbohydrates. Moreover, participants in the treatment arm recorded daily body 
weight and received weekly written feedback commenting on their individual weight progress. Beyond these 
Figure 2.  Principal component analysis. The principal component analysis (PCA) plot was used to visualize 
the variance in gene expression data in participants of the treatment arm at baseline (red symbols) and after the 
6-month intervention period (blue symbols). The first principal component (PC1) on the x-axis is the linear 
combination comprising the largest percentage of variation in the dataset. The second principal component 
(PC2), located on the y-axis, captures the second largest percentage of variance. PCA was generated using the 
affycoretools package in R (R Core Team, 2018, R: A Language and Environment for Statistical Computing. R 
Foundation for Statistical Computing, Vienna. https ://www.R-proje ct.org).
6
Vol:.(1234567890)
Scientific Reports |        (2020) 10:17855  | https://doi.org/10.1038/s41598-020-74973-2
www.nature.com/scientificreports/
instructions, no special diet, e.g. specific macronutrients, was recommended. Hence, it is unfortunately not 
possible to separate the effects of the different components of the 6-month-long telemonitored lifestyle-induced 
weight loss program on  CD14+ cell frequencies. However, the decline in  CD14+ cells correlated moderately with 
parameters that reflect weight loss and inflammatory response, such as BMI, hsCRP and leptin. These obser-
vations suggest that lifestyle-induced weight loss is sufficient to reduce obesity-associated inflammation and 
peripheral blood monocyte frequencies.
Considering that monocyte gene expression might be driven by inflammatory signals, we performed a hsCRP 
subgroup analysis including monocytes from individuals in which the baseline hsCRP was reduced by at least 
50%. This analysis did not reveal genes that were differentially expressed following lifestyle-induced weight loss. 
Considering the markedly reduced body weight and the unaltered gene expression profile in the hsCRP sub-
group analysis, we propose that altered gene expression in peripheral blood monocytes is independent of weight 
loss-associated attenuation of chronic low-grade inflammation. However, this subgroup analysis included fewer 
samples (N = 16) than the calculated sample size (N = 34), which is a major limitation.
Obesity is associated with increased accumulation of ATMs from around 5% in lean up to 50% in obese 
 individuals5. Migration of peripheral blood monocytes into adipose tissue has been proposed as a major source 
of ATMs. While the current study cannot directly evaluate this hypothesis, comparative analyses of gene expres-
sion of paired  CD14+ monocytes and subcutaneous adipose tissue samples before and after weight loss did not 
identify common genes differentially regulated in both sample types. Our results support the notion that changes 
observed in  CD14+ cells were specific for this cell population and that macrophages in the adipose tissue respond 
differently at the gene-expression level upon weight loss.
Recent studies demonstrated that the majority of tissue resident macrophages originate from embryonic 
progenitor  cells29. In addition, preadipocytes have been shown to differentiate locally into macrophage-like cells 
that have phagocytic activity and that express macrophage-specific antigens such as F4/80, Mac-1, CD80, CD86, 
and  CD4530,31. Indeed, it is now widely accepted that local processes are responsible for ATM accumulation in 
 obesity32, a conclusion supported by our finding showing that weight loss is associated with specific gene expres-
sion alterations in peripheral  CD14+ cells and that there is no overlap between  CD14+ monocytes and adipose 
tissue gene expression upon weight loss.
The strengths of the current study include the prospective study design, a well-characterized study population 
with no differences between groups at baseline, a strong effect regarding weight loss as the primary outcome 
(12.6%) and robust statistical analyses of paired datasets (before and after intervention). In particular, the latter 
eliminates the changes in interindividual random differences as a source of accidental findings. All analyses 
were conducted in a blinded manner, and laboratory measurements were performed according to standard 
Table 3.  Differentially expressed genes in paired  CD14+ samples and paired adipose tissue samples after the 
6-month intervention period. The top 20 differential expressed genes (DEGs) in  CD14+ samples are listed. 
Gene expression profiles were compared between  CD14+ cells and corresponding subcutaneous adipose tissue 
samples (N = 36) and identified DEGs were ranked. LogFC log2 fold change, adj.p.Val false discovery rate 
adjusted p-value.
Gene name
Paired  CD14+ samples: top 20 DEGs
Paired adipose tissue samples
Ranking of same 20 DEGs
Rank logFC aveExpr adj.p.Val Rank logFC aveExpr adj.p.Val
ZRANB1 1  − 0.30 9.15 0.006 4216  − 0.19 9.05 0.404
RNF25 2 0.24 7.54 0.049 22,263 0.04 7.10 0.856
RB1CC1 3  − 0.16 9.21 0.049 23,485  − 0.04 8.25 0.870
KMT2C 4  − 0.20 10.36 0.049 898  − 0.27 8.19 0.146
MIR125A 5 0.17 3.93 0.060 11,422  − 0.08 3.34 0.663
EDEM1 6  − 0.22 8.68 0.070 15,779  − 0.04 6.76 0.757
ATP13A3 7  − 0.29 8.59 0.070 33,186 0.01 8.51 0.961
JMJD1C 8  − 0.24 10.47 0.070 10,763  − 0.10 8.93 0.647
SMEK1 9  − 0.16 9.31 0.070 2797  − 0.11 7.57 0.318
EIF3J 10  − 0.19 8.10 0.070 22,419  − 0.05 7.41 0.857
FBXO11 11  − 0.13 9.71 0.070 4751  − 0.12 8.84 0.434
CHD1 12  − 0.26 9.97 0.070 12,159  − 0.11 7.44 0.678
CCNT1 13  − 0.18 8.66 0.070 16,754  − 0.04 7.86 0.770
ARIH1 14  − 0.14 10.46 0.070 1907  − 0.15 9.72 0.246
USP9X 15  − 0.16 8.83 0.070 37,022 0.00 8.42 0.992
HGSNAT 16  − 0.15 9.54 0.082 8978  − 0.08 9.19 0.598
SESTD1 17  − 0.22 9.27 0.082 7018  − 0.12 9.83 0.538
TRPC6 18 0.15 4.27 0.086 7733  − 0.13 4.79 0.561
WDFY3 19  − 0.14 10.02 0.104 7355  − 0.09 8.94 0.551
BTAF1 20  − 0.14 9.87 0.106 294  − 0.23 8.05 0.066
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operating protocols, yielding high-quality data. Given the stringent selection criteria we only enrolled middle-
aged Caucasian male participants with MetS for the study. This approach, while being a strength with respect to 
data validity, however precludes generalization of the data to e.g. to females, other racial/ethnic groups, older 
or younger individuals, or to individuals without MetS. A potential limitation of the study is our approach to 
increase sample size for differential gene expression analyses by adding participants of the original control arm, 
who participated in the subsequent follow-up treatment, to the treatment arm. However, baseline characteristics 
and weight loss were highly comparable between both groups, making this approach feasible. Moreover, our 
analysis is limited to gene expression. We did not address phenotypical alterations in circulating monocytes 
induced by posttranscriptional or posttranslational mechanisms, such as miRNA or receptor-ligand interactions. 
Furthermore, we cannot exclude changes in gene expression in subgroups of  CD14+ monocytes.
In conclusion, lifestyle-induced weight loss is associated with altered gene expression in  CD14+ peripheral 
blood monocytes, which may regulate ubiquitination, autophagy and epigenetic modifications.
Methods
Research design and study population. The study is embedded in a prospective, two-armed, con-
trolled, monocentric, randomized, 6-month intervention trial aiming to identify changes in gene expression 
in individuals with MetS following lifestyle-induced weight loss. For this purpose, paired (i.e., before and after 
lifestyle-induced weight loss) blood samples and subcutaneous adipose tissue biopsies were collected at the 
Institute of Clinical Chemistry and Pathobiochemistry, Otto-von-Guericke University, Magdeburg, Germany. 
The trial was registered at the German Clinical Trials Register (ICTRP Trial Number: U1111-1158-3672)11.
The trial included nonsmoking, nondiabetic men aged between 45 and 55 years with MetS as defined by 
the National Cholesterol Education Program Adult Treatment Panel III guidelines: abdominal obesity (waist 
circumference > 102 cm or BMI > 30 kg/m2) combined with at least two of the following criteria: fasting tri-
glyceride concentration ≥ 1.7 mmol/l; high-density lipoprotein (HDL) cholesterol < 1.05 mmol/l; fasting glu-
cose ≥ 5.6 mmol/l; blood pressure ≥ 130/85 mmHg or treatment for hypertension. Exclusion criteria were smok-
ing, type 2 diabetes mellitus, a history of surgical procedure for weight loss, severe renal dysfunction (creatinine 
concentration > 2.0 mg/dl), known liver disease, obesity of known endocrine origin or inability to walk at least 
30 min per day. Out of 133 individuals who were recruited by an advertisement in a regional newspaper and 
screened for inclusion or exclusion criteria from May 2012 to August 2012, 74 individuals were selected for the 
trial. All participants underwent a structured education program about diet and the importance of physical 
Figure 3.  Principal component analysis of  CD14+ and subcutaneous adipose tissue samples before and after 
weight loss. The principal component analysis (PCA) plot was used to visualize the variance in gene expression 
between corresponding  CD14+ and subcutaneous adipose tissue samples each before (red, blue) and after 
(green, purple) weight loss (N = 36). The first principal component (PC1) on the x-axis is the linear combination 
comprising the largest percentage of variation in the dataset. The second principal component (PC2), located 
on the y-axis, captures the second largest percentage of variance. PCA was generated using the affycoretools 
package in R (R Core Team, 2018, R: A Language and Environment for Statistical Computing. R Foundation for 
Statistical Computing, Vienna. https ://www.R-proje ct.org).
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activity. Individuals were randomly assigned to a 6-month-long telemonitored lifestyle-induced weight loss 
program (treatment arm, https ://www.abcpr ogram m.de33) or a control arm as described  previously11.
Participants of the treatment arm were advised to lower their calorie intake by 500 kcal/day and to perform a 
low-carbohydrate diet with preference for low-GI carbohydrates, as previously  described33. Regarding exercise, 
participants were advised to increase their usual daily physical activity, but to keep the pulse below 120/min. 
Moreover, participants recorded daily body weight and received weekly written feedback commenting on their 
individual weight progress. This weight loss program was first shown to be effective in obese parents and obese 
 children34.
At baseline and after 6 months, subcutaneous adipose tissue biopsies and peripheral blood samples were 
obtained from participants of both arms. All study participants were examined after 3 months using fasting 
blood glucose and glycated hemoglobin (HbA1c) to exclude new onset type 2 diabetes mellitus during the study.
Treatment arm Control arm
26 individuals of the control arm who 
underwent treatment during the 6 
month follow-up period 
- 1 did not follow the study protocol 
- 3 missing RNA samples 
  (refused 2nd CD14+ collection)
- 5 RNA low quality/yield 
= 17 paired monocyte samples
- 9 participants weight loss > 0.5 kg
= 12 paired monocyte samples
hsCRP subgroup:
individuals with > 50% reduced 
hsCRP upon treatment
= 16 paired monocyte samples
gene expression profiling by microarray
= 39 paired monocyte samples
133 individuals screened for 
inclusion or exclusion criteria 
74 individuals were selected for 
the trial and randomly assigned
37 individuals:
- 2 did not follow the study protocol 
- 2 declined for undisclosed reasons
33 individuals completed the study
- 5 missing RNA samples 
  (refused 2nd CD14+ collection)
- 6 RNA low quality/yield 
= 22 paired monocyte samples
37 individuals:
- 4 did not follow the study protocol   
  (refused 1st biopsy)
- 3 left because not randomized to  
  the treatment arm
30 individuals completed the study
- 3 missing RNA samples 
  (refused 2nd CD14+ collection)
- 6 RNA low quality/yield
= 21 paired monocyte samples
Figure 4.  Schematic study design. The study is embedded in a two-armed, controlled, monocentric, 
randomized, 6-month intervention trial. Paired blood samples were collected before and after the 6-months 
intervention period. Individuals of the control arm were invited during the follow-up period to participate 
subsequently in the treatment arm. Samples from participants of the control arm who lost more than 0.5 kg 
of weight during the study period and samples with low RNA quality were excluded from analysis. In total, 
39 samples (treatment arm) and 12 samples (control arm) were used for unbiased gene expression profiling 
of purified  CD14+ monocyte samples. Within the treatment arm, a subgroup characterized by an at least 50% 
reduction of elevated hsCRP following weight loss was analyzed (N = 16, hsCRP subgroup).
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Thirty participants in the control and 33 participants in the treatment arm completed the  study11. For gene 
expression profiling, only paired sample sets with high RNA quality were selected, resulting in 22 paired mono-
cytes samples in the treatment arm. During the follow-up, participants initially assigned to the control arm were 
offered enrollment in the treatment arm. 26 individuals participated in the subsequent 6-month weight loss 
program and received exactly the same weight loss intervention as participants of the initial treatment group 
(Supplementary Table S3). This yielded in 17 additional paired monocyte samples with high RNA quality. In 
the control arm, considering weight loss in participants as a possible confounding factor for data analysis, par-
ticipants with weight loss of more than 0.5 kg during the study period were excluded from the analysis. Overall, 
this resulted in 39 and 12 paired sample sets from the treatment arm and the control arm, respectively, which 
were used for data analysis as shown in Fig. 4.
The gene expression profiles in paired  CD14+ blood monocytes samples and corresponding subcutaneous 
adipose tissue biopsies (N = 36) were analyzed before and at the end of the 6-month intervention period in both 
arms.
Clinical and laboratory measurements. Body weight and height were measured by qualified medical 
personnel according to standard operating protocols before and after 6 months. Body composition was ana-
lyzed by dual-energy X-ray absorptiometry in participants of the initial treatment group (N = 22) and the initial 
control group (N = 12). All blood samples were collected in the morning (8 am to 9 am) from the antecubital 
vein after a 12-h overnight fast. Glucose was determined in sodium fluoride plasma. Laboratory measurements 
were performed at the Institute of Clinical Chemistry and Pathobiochemistry, OvGU, Magdeburg, Germany, as 
described  previously11. Concentrations of high sensitive CRP (hsCRP) were analyzed by a particle-enhanced 
immunoturbidimetric assay (Cobas c 501, Roche Diagnostics). Interleukin-6 was analyzed by a sandwich elec-
trochemiluminescent immunoassay (ECLIA, Cobas e 601, Roche Diagnostics). Leptin concentrations were 
quantified using a commercially available enzyme linked immunosorbent assay (ELISA, according to the manu-
facturer’s instructions, BioVendor; Czech Republic) with an intraassay CV of 5.9%, interassay CV of 5.6% and a 
lower limit of detection of 0.2 ng/ml.
CD14+ monocyte preparation. Peripheral blood mononuclear cells (PBMCs) were obtained from buffy 
coats of EDTA blood samples from overnight-fasted participants before and after 6 months. Twenty milliliters of 
whole blood was collected by standard venipuncture into blood collection tubes that contained  K2EDTA. Each 
tube was diluted with two equal volumes of PBS. The diluted cell suspension was overlaid onto 15 ml of Ficoll-
Paque and centrifuged (30 min; 400×g). The cell suspension was washed 3 times with PBS to remove platelets. 
To separate monocytes from lymphocytes, an additional iso-osmotic Percoll centrifugation was  employed35. The 
monocyte phase was collected, and a positive selection of  CD14+ cells was performed by adding MACS colloidal 
superparamagnetic microbeads (Miltenyi Biotec, Germany) conjugated with monoclonal anti-human CD14 in 
MACS buffer according to the manufacturer´s instructions. Briefly, after incubation of cells and microbeads 
(15 min at 4 °C), cells were washed with MACS buffer, resuspended, and loaded onto the separation column. 
Trapped  CD14+ PBMCs were eluted, centrifuged, washed with PBS and stored in RNAlater (Sigma-Aldrich) 
at − 80 °C. A proportion of eluted cells was used to determine cell number and purity using flow cytometry. The 
purity was assessed by determining the number of cells that were positive for CD14 (Mouse Anti-Human CD14, 
BD, Catalog No. 555397) and negative for CD3 (Mouse Anti-Human CD3, eBioscience, Catalog No. 16-0037-
85). The obtained  CD14+ monocyte samples were sent to the Integrated Biobank of Luxembourg (IBBL) for 
storage at − 80 °C and RNA extraction.
RNA quality assessment. RNA extraction and quality assessment were performed at the IBBL. Total RNA 
was extracted using the standard RNA extraction method with TRIzol (Invitrogen). The RNA concentration in 
each sample was assayed with an ND-1000 spectrophotometer (NanoDrop). RNA quality was assessed using an 
Agilent 2100 Bioanalyzer with an Agilent RNA 6000 nanokit (Agilent Technologies). The assessment of RNA 
quality was conducted to standardize the process of RNA integrity interpretation and to select samples that were 
suitable for downstream microarray analysis. The Bioanalyzer software algorithm calculates an RNA Integrity 
Number (RIN) on the basis of different regions of the entire electrophoretic trace of the RNA sample (pre-, 5S-, 
fast-, inter-, precursor-, post-region) and peaks (18S, 28S). Electropherograms are classified by a numeric system 
with 1 being the most degraded profile and 10 being the most intact. For microarray analysis, we selected only 
samples with RIN values above 8 (Table 2).
Microarray analysis. Processing of RNA and transcriptomic profiling was performed at the European 
Molecular Biology Laboratory (EMBL). A total of 300 ng of total RNA was used to prepare labeled and purified 
sense-strand cDNA (Ambion WT Expression Kit). Reactions from all samples yielded sufficient cDNA for sub-
sequent microarray analysis. Samples were hybridized to whole-transcript arrays (Affymetrix GeneChip Human 
Gene 2.0 ST Arrays) covering > 33,500 coding transcripts that include transcript variants and alternative splicing 
events. Hybridization was carried out according to the standard protocol provided by the manufacturer.
Statistical analysis. The primary aim of this study was to characterize gene expression profiles of  CD14+ 
monocytes before and after lifestyle-induced weight loss in well-defined individuals with MetS and to detect 
differentially expressed genes using microarray analysis. To calculate the required sample size the following sam-
ple size computational model was used: (https ://bioin forma tics.mdand erson .org/Micro array Sampl eSize /Micro 
array Sampl eSize .aspx). This algorithm takes normal distributed gene expression on log scale, false positive genes 
and independent gene measurements into consideration. We used GeneChip Human Gene 2.0 ST Arrays from 
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Affymetrix which encode 40K RefSeq transcripts in this study. We applied 1 as the number of acceptable false 
positives in the experiment and selected a desired fold difference of 0.5. Our desired power is 0.95, which indi-
cates that 95% of differentially expressed genes are likely to be detected by the experiment. We applied a level of 
0.7 as a realistic value for standard deviation of the gene intensity measurement on the base-2 logarithmic scale 
for genes that are expressed at moderate to high  levels36. This calculation results in a sample size per group of 
N = 34 for before and after weight loss.
Nonparametric tests were applied for all statistical analyses of clinical data. Data are given as the median and 
interquartile range (IQR). Differences between independent samples (treatment arm vs. control arm before or 
after 6 months, respectively) were analyzed by the Mann–Whitney U test. Paired samples were analyzed by the 
Wilcoxon Signed-Rank test. Correlations between relative changes during the 6-month intervention period were 
assessed by Spearman’s rank correlation. All calculations were performed using the IBM SPSS Statistics, version 
22.0 (IBM Corporation, Armonk, NY, USA). The results were considered significant at p < 0.05.
Gene expression analysis. Raw data were preprocessed with the Robust Multiarray Average algorithm 
(RMA; convolution background correction, quantile normalization and summarization based on the median 
polish algorithm, Supplementary Fig. S2)37. Differentially expressed genes were identified using the limma pack-
age in  R38, which fits a linear model for each gene based on the given series of arrays, creates an appropriate 
contrast matrix to perform all pairwise comparisons, computes estimated coefficients and standard errors for 
a given set of contrasts and computes moderated t-statistics and log-odds of differential expression by empiri-
cal Bayes. Correction for multiple testing was performed using the Benjamini–Hochberg method to control 
the false discovery  rate39. The principal components analysis (PCA) plot was generated using the affycoretools 
package in  R40. The statistical procedure is a data compression method that allows for the transformation of a 
large set of possibly related variables into a new low-dimensional coordinate system that still contains most of 
the information.
Ethics statement. This study was approved by the ethics committee at Otto-von-Guericke University, 
Magdeburg, Germany (No. 78/11). Written informed consent was obtained from all study participants. All 
human investigations were conducted according to the principles expressed in the Declaration of Helsinki.
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